BrightInsight, which helps drug/device makers build apps for patients and doctors, raises $101M Series C led by General Catalyst, source says at $750M valuation
Context & Ripple Effects
BrightInsight's raise lands at the peak of a 2021 funding wave in patient-facing health software: on the very same day, Rightway closed a $100M Series C at a $1.1B valuation, giving the round an immediate benchmark — BrightInsight's reported $750M is below that mark despite a nearly identical check size.
The company occupies the compliance layer between drug/device makers and their apps, a position validated downstream by Medable's $304M Series D months later in clinical-trial software, and by Beta Bionics' $100M round after winning FDA approval for its dosing software — evidence that regulated health software commands late-stage capital when it clears regulatory bars.
First-order effects
- General Catalyst adds a regulated-health platform bet to its portfolio, and BrightInsight gains the balance sheet to expand its managed app infrastructure across more pharma and device clients.
Second-order effects
- Drug and device makers weighing build-vs-buy get a funded, scaled vendor option, pressuring internal digital-health teams and pushing adjacent platforms like Medable to deepen their hold on pharma workflows.
Third-order effects
- If the pattern holds — FDA clearance converting into nine-figure rounds, as Beta Bionics shows — regulatory approval itself becomes the asset that attracts growth capital, structuring health software markets around compliance moats rather than consumer distribution.
The trend: Regulated health software is drawing ever-larger venture checks as compliance capability, not consumer reach, becomes the scarce asset investors pay up for.